Core Viewpoint - Zhejiang Kangnbei Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, aimed at treating diabetic nephropathy [1][2]. Group 1: Drug Clinical Trial Approval - The drug TFA003 is classified as a traditional Chinese medicine under categories 2.1 and 2.3, with the application for clinical trials focusing on oral administration for diabetic nephropathy [1][2]. - The approval notice indicates that the drug meets the requirements for drug registration and can proceed with clinical trials after refining the trial protocol [1]. Group 2: R&D Status - The company has invested approximately RMB 29.57 million in the research and development of TFA003, which has shown significant efficacy in improving renal function indicators in animal studies [2]. - The drug has the potential to be developed as a new traditional Chinese medicine for diabetic nephropathy, showing improvements in glomerular filtration and renal tubular reabsorption functions [2]. Group 3: Market Situation - There are currently few drugs available for the treatment of diabetic nephropathy in both domestic and international markets, primarily relying on antihyperglycemic and antihypertensive medications [3][4]. - The market for traditional Chinese medicine related to diabetic nephropathy is projected to reach a total sales volume of RMB 27 billion in 2024, reflecting a year-on-year growth of 5.25% [6].

Core Viewpoint - The company announced that its wholly-owned subsidiary, Hangzhou Kangnbei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, which are aimed at treating diabetic nephropathy [1] Group 1 - The clinical trial approval is for TFA003 tablets, which are classified as traditional Chinese medicine under categories 2.1 and 2.3 [1] - The administration route for TFA003 is oral, and the optimal dosage will be confirmed after the completion of clinical trials [1] - Preliminary pharmacological and pharmacokinetic animal studies indicate that TFA003 has significant therapeutic effects on diabetic nephropathy, improving renal function indicators in urine and blood, as well as enhancing glomerular filtration and tubular reabsorption functions [1] Group 2 - The company has invested approximately RMB 29.57 million in the research and development of TFA003 to date [1] - The drug shows potential for development as a new traditional Chinese medicine for diabetic nephropathy based on its efficacy and safety profile demonstrated in preclinical studies [1]